Company / EPS (Diluted)
Bicara Therapeutics Inc. EPS (Diluted) History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$4.05
FY2024
5-year range
-$89.61 / -$4.05
FY2023-FY2024
Trend
+95.5%
vs FY2023
Sector context
#165 of 204
Health Care
What the data says
Bicara Therapeutics Inc.'s eps (diluted) of $-4.05 is lower than 81% of companies in the Health Care sector (FY2024).
Based on SEC 10-K filings.
-4.05 in FY2024.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 19% in Health CareTop 81% of 204This company -$4.05 Sector average -$0.98
▼
-313.4% below sector average
Key checks
Key Insights
- In FY2024, eps (diluted) increased 95.5% year-over-year.
- Ranks #165 out of 204 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 11.58 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$4.05 | +95.5% |
| FY2023 | -$89.61 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026